Mateon Therapeutics (OTCMKTS:MATN) was downgraded by HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued to investors on Friday, Marketbeat.com reports.
MATN has been the topic of a number of other reports. Zacks Investment Research raised Mateon Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a report on Saturday, April 21st. ValuEngine raised Mateon Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd.
OTCMKTS:MATN opened at $0.14 on Friday. The stock has a market cap of $8.26 million, a price-to-earnings ratio of -0.27 and a beta of 2.14. Mateon Therapeutics has a 52 week low of $0.09 and a 52 week high of $0.55.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia.
Further Reading: Investing in Growth Stocks
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.